) recently inked a distribution agreement with the privately held
Zyomyx, Inc. Following the deal, Mylan gained rights to
distribute Zyomyx's point-of-care (POC) CD4 T-cell count test in
developing markets. The CD4 test is applicable for patients
suffering from HIV.
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis
SIMCERE PHARMAC (SCR): Free Stock Analysis
To read this article on Zacks.com click here.
Pursuant to the deal, Mylan has made a strategic equity
investment in the private entity. We note that the portable,
easy-to-use, low-cost test is undergoing the final stages of
development and is expected to be launched shortly, assuming
approval. Mylan intends to distribute the product in developing
markets along with its wide range of high quality, low-cost
generic antiretroviral drugs to facilitate HIV treatment in those
Furthermore, Mylan has inked a Global Access Commitment with one
of the investors in Zyomix, Bill & Melinda Gates Foundation,
to facilitate easy access of the POC CD4 technology to HIV
patients in markets, where the disease is highly prevalent.
We note that Mylan was also in the news recently when it launched
a wide range of women's care products in the highly sought after
emerging market- India.
Moreover, the already established generic portfolio at Mylan was
further strengthened when it launched its generic version of
) erectile dysfunction drug Viagra (sildenafil citrate) in eleven
European nations last month. Mylan's generic unit has seen quite
a few launches over the past few months. Another generic player,
Dr. Reddy's Laboratories Ltd.
), too has been making multiple generic launches over the past
Mylan carries a Zacks Rank #3 (Hold).
Simcere Pharmaceutical Group
) appears to be more attractive with a Zacks Rank #2 (Buy).